These observations are clinically significant for AA men, who are more frequently diagnosed with prostate cancer at a younger age (< 55 years) than EA men [6, 63], and are more likely to remain on a life-long AR-targeted therapy. This evidence concerns the gene AR and prostate carcinoma.